看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。0 @: o: ?$ @; J8 o% b: z2 f' n
" \! \! \5 ?& k! I5 T9 x/ v
( }. U9 d7 q# Q# `# s' M
Currently available feasibility data for possible combination strategies. 3 z4 U/ h: Q8 t' _
————————————————————————————————
( H D3 ]6 O, @2 y# lCombination Feasibility according to preliminary data
) i) Q' V/ [% ^/ L7 {' n——————————————————————————————————; A! X0 p) i* A0 w, w: n+ C- v
Bevacizumab + sorafenib Yes, reduced dose 4 x& _* J3 x2 {3 W9 y5 ^
Bevacizumab + sunitinib† No ! K: ~$ N2 z' r
Bevacizumab + temsirolimus Yes % {# @' e% x' w t
Bevacizumab + everolimus Yes ( `( \5 }3 b' Q; d6 }; }
Sorafenib + sunitinib ?
; A7 l/ i* o- E0 j, A9 c! s4 gSorafenib + temsirolimus Yes, reduced dose , i! D6 Q% d0 |7 d h% z
Sorafenib + everolimus Yes, reduced dose 8 P$ L; C i% U4 D- r
Sunitinib + temsirolimus† No
& ^/ b1 O7 L; d/ o# ISunitinib + everolimus ?
4 T/ o+ F6 Z+ |Temsirolimus + everolimus ?
& ` Q' o5 g. e( u) u% f! W————————————————————
* S* L2 y6 @7 e8 j1 f; m†Led to US FDA warning.5 Z8 i0 v& P K) M0 y, r6 N
?: As yet unattempted combination.
. W( f" c/ e' t/ _2 {/ |4 o |